Table 3. Comparisons of changes in each variable from baseline at 12-month visit in the patients with a higher FIB-4 index at baseline in the TRT and control groups.
| Variable | TRT group (n=59) | Control group (n=67) | p-value |
|---|---|---|---|
| Weist circumference (cm) | -0.8±3.2 | 0.8±3.7 | 0.00569 |
| BMI (kg/m2) | 0.0±0.9 | 0.0±1.1 | 0.476 |
| Fat volume (kg) | -1.3±4.9 | 0.5±3.7 | 0.0116 |
| Platelet (1,000/µL) | 9.3±29.6 | -0.6±22.9 | 0.0194 |
| AST (IU/L) | -0.9±6.8 | -0.5±9.2 | 0.387 |
| ALT (IU/L) | 0.2±8.9 | 1.0±11.3 | 0.324 |
| FBS (mg/dL) | -0.8±44.1 | 11.5±42.1 | 0.0588 |
| HbA1c (%) | -0.1±0.5 | 0.1±0.4 | 0.101 |
| T-Chol (mg/dL) | -3.3±21.2 | -3.5±24.0 | 0.481 |
| TG (mg/dL) | -14.4±48.6 | 3.6±40.0 | 0.0127 |
| HDL-Chol (mg/dL) | -1.5±7.5 | -1.5±7.5 | 0.490 |
| FIB-4 index | -0.10±0.39 | 0.04±0.44 | 0.0311 |
Values are presented as mean±standard deviation.
TRT: testosterone replacement therapy, BMI: body mass index, AST: aspartate aminotransferase, ALT: alanine transaminase, FBS: fasting blood sugar, HbA1c: hemoglobin A1c, T-Chol: total cholesterol, TG: triglyceride, HDL-Chol: high-density lipoprotein cholesterol, FIB-4: Fibrosis-4.